Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations
3.10.2024 16:00:00 EEST | Business Wire | Press release
Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/
Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire)
AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools to generate code meet high standards of quality and security. Today, bad code is already estimated to cost businesses more than a trillion dollars, making it critical for AI-generated code, which promises to increase the volume of code written, to be comprehensively checked for quality and security issues.
“AI is transforming the way developers work, streamlining processes, and reducing the toil associated with writing code. As the adoption of AI coding assistants grows, however, we are seeing a new issue emerge: code accountability. AI-generated code needs review by developers, but accountability for doing this is increasingly diluted. As a result, we’re seeing the review step frequently being shortchanged,” said Tariq Shaukat, CEO of Sonar. “With AI Code Assurance, we’re helping organizations ensure that AI written code receives the high level of quality and security review that you would expect from your developers.”
AI CodeFix allows developers to seamlessly resolve issues detected by Sonar's code analysis engine with a single click, directly within their workflow. The AI-powered fix recommendations help streamline developer workflows, speed up issue remediation, and improve the developer experience. As leading research has established, developer experience improves with the automation that AI provides. For example, McKinsey reported that developers using generative AI tools in their work stream are “twice as likely to report overall happiness, fulfillment, and a state of flow” than those who aren’t.
“AI CodeFix helps developers streamline their workflow and ramp up their productivity. Rather than switching between solutions or manual efforts, we’re putting remediation options for Sonar-identified issues right in front of the people working on them – and giving them the ability to fix the issues in an instant. We’re excited to see how our users adopt this capability and better understand how we can further integrate AI into our solutions to improve the developer experience,” said Fabrice Bellingard, VP of Product at Sonar.
The features are currently available for both SonarQube and SonarCloud.
AI Code Assurance for Confidence in Code Quality
With AI Code Assurance for SonarQube and SonarCloud, developers can be confident that their AI-generated code is clean and secure. By implementing the Sonar AI Code Assurance workflow, organizations have the assurance that all code (AI-generated and human-developed) has been thoroughly scanned for issues and that projects leveraging AI tools are meeting high standards of quality and security.
AI Code Assurance capabilities include:
- Project Tagging: Developers can easily tag projects that contain AI-generated code, initiating a comprehensive analysis through the Sonar AI Code Assurance workflow.
- Quality Gate Enforcement: An optimized quality gate for AI-generated code ensures that only code meeting strict quality and security standards is approved for production.
- AI Code Assurance Approved Badge: Projects that pass the quality gate receive a badge signifying that the code has gone through a rigorous AI-ready analysis.
AI CodeFix for Fast Issue Remediation
Fast-paced software development environments require solutions that enhance productivity, reduce time-to-market, and maintain high code quality. Today, millions of Sonar users can detect and fix issues in their code leveraging Sonar’s database of code rules and best practices. Now, at the click of a button, developers can use AI CodeFix to automatically generate solutions to issues in the same SonarQube and SonarCloud user interface where they review issues.
AI CodeFix capabilities include:
- Instant Code Fixes: Minimize manual debugging efforts and increase productivity by automatically generating code fix suggestions.
- Contextual Understanding of Sonar findings: Leverages LLMs to understand code context and provide relevant fixes.
- Seamless Integration: Developers fix issues directly within their IDE using SonarLint connected mode, ensuring a smooth workflow.
- Continuous Learning: Ongoing suggestion improvements based on user feedback
- Multi-Language Support: Supports flagship programming languages such as Java, JS/TS, C#, Python, and C/C++.
AI Code Assurance is now available on SonarQube and will be generally available in SonarCloud by the end of October. AI CodeFix is available for early access in SonarQube Enterprise Edition, SonarQube Data Center Edition, and SonarCloud Team and Enterprise plans.
For more information on the new features, visit our AI features page at https://www.sonarsource.com/solutions/ai/.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003439224/en/
Contacts
Media
Katie Hyman
Senior PR Manager for Sonar
(707) 291-1469
press@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom